AE 3763

Drug Profile

AE 3763

Latest Information Update: 07 Feb 2008

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class Imidazolines; Pyrrolidines
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome

Most Recent Events

  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 20 Nov 2004 AE 3763 is available for out-licensing (http://www.dainippon-pharm.co.jp)
  • 20 Sep 2002 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top